Arbutus Biopharma Q4 EPS $(0.12), Inline, Sales $2.15M Miss $4.79M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arbutus Biopharma (NASDAQ:ABUS) reported Q4 earnings with EPS of $(0.12), meeting analyst estimates but with sales of $2.15M, missing the $4.79M estimate. This represents a 14.29% improvement in EPS and a 65.65% decrease in sales year-over-year.
February 29, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arbutus Biopharma reported Q4 EPS of $(0.12), aligning with estimates, but sales of $2.15M missed the $4.79M estimate, indicating a significant revenue shortfall.
The EPS meeting estimates might provide some stability, but the significant miss in sales revenue by 55.22% compared to expectations and a 65.65% decrease from the previous year's sales could lead to negative investor sentiment in the short term. This substantial miss in revenue expectations is likely to overshadow the EPS performance, potentially leading to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100